Tobramycin is under clinical development by Enteris BioPharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tobramycin’s likelihood of approval (LoA) and phase transition for Urinary Tract Infections took place on 18 Oct 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tobramycin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tobramycin overview

Tobramycin is under development for the treatment of uncomplicated urinary tract infections (uUTIs). It is an aminoglycoside and administered through the oral route in the form of the tablet. The drug candidate is developed based on peptelligence platform.

Enteris BioPharma overview

Enteris BioPharma (Enteris) operates as a biotechnology company. It specializes in oral peptide drug delivery technology for the treatment of patients with postmenopausal osteoporosis. The company technology comprises peptelligence and properma. Its peptelligence improves oral bioavailability through a smart combination of pH-lowering, charge dispersal, membrane wetting, and solubilizing agents in a highly scalable solid oral dosage form without making physicochemical modifications to the API. Enteris Properma improve solubility and permeability of small molecules which utilizes an enteric coating surrounding a tablet core containing the API with solubilizing agents. Enteris is headquartered in Boonton, New Jersey, the US.

Quick View Tobramycin LOA Data

Report Segments
  • Innovator
Drug Name
  • Tobramycin
Administration Pathway
  • Oral
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.